Anticancer agent 210

| Cat. No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage: | HY-162481 C ₃₁ H ₃₁ BrFN ₇ O ₃ 648.53 Apoptosis Apoptosis Please store the product under the recommended conditions in the Certificate of Analysis. | |
|---|---|--|
|---|---|--|

| Description | Anticancer agent 210 (Compound 7a) is a Gefitinib (HY-50895) derivative. Anticancer agent 210 inhibits proliferation, | | | |
|-------------|---|--|--|--|
| | ingration and cotony form | | | |
| In Vitro | Anticancer agent 210 (0-32 μM, 48 h) inhibits proliferation of lung cancer cells NCI-H1299, A549, NCI-H1437, with IC ₅₀ s of 3.94, 3.16 and 1.84 μM, respectively ^[1] . Anticancer agent 210 (2-16 μM, 48 h) exhibits slightly cytotoxicity in normal hepatocytes L02, with IC ₅₀ of 18.87 μM, and a survival rate >60% ^[1] . Anticancer agent 210 (4-16 μM, 48 h) induces apoptosis of non-small cell lung cancer cells through Bcl-2/caspase3/PARP pathway, inhibits NSCLC cell migration through suppression of MMP9 protein expression ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay ^[1] | | | |
| | Cell Line: | NCI-H1299, A549, NCI-H1437 | | |
| | Concentration: | 0-32 μΜ | | |
| | Incubation Time: | 48 h | | |
| | Result: | Inhibited cell proliferation. | | |
| | Western Blot Analysis ^[1] | | | |
| | Cell Line: | NCI-H1299 | | |
| | Concentration: | 4-16 μΜ | | |
| | Incubation Time: | 48 h | | |
| | Result: | Inhibited expressions of Bcl-2, caspase9 and MMP9, upregulated levels of cleaved caspase 3 and PARP. | | |
| | | | | |
| In Vivo | Anticancer agent 210 (400 mg/kg, p.o., single dose) exhibits no significant toxicity in Kunming mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | | |
| | | | | |



REFERENCES

[1]. Gao E, et al., Discovery of gefitinib-1,2,3-triazole derivatives against lung cancer via inducing apoptosis and inhibiting the colony formation. Sci Rep. 2024 Apr 22;14(1):9223.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA